LifeScience Antibody Drug Conjugates
Turning Signals into Cures: The Big Data Blueprint for Cell Therapy Factories
Cell therapy manufacturing is entering a data-driven era, as the industry grapples with complex production processes, high costs, and the need for personal...
October 07, 2025 | Analysis
WuXi XDC Co-Hosts 2025 BPD Singapore Summit Showcasing Innovation in Bioconjugates and Global Biopharma Collaboration
The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully conclude...
September 30, 2025 | News
WuXi Biologics Launches TrueSite TI™, a Next-Generation Targeted Integration Cell Line Platform Redefining Biologics Development
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone scre...
September 29, 2025 | News
Hengrui Pharma Grants Glenmark Exclusive Global Licence for HER2-Targeted ADC Trastuzumab Rezetecan
Hengrui Pharma, a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced that it has entered ...
September 25, 2025 | News
Eli Lilly to Invest $5 Billion in New Virginia API and Bioconjugate Manufacturing Facility
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other ad...
September 17, 2025 | News
China’s Biocytogen Licenses Fully Human Antibody to Tubulis for Novel ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel ...
September 17, 2025 | News
Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate
Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...
September 16, 2025 | News
Akeso Doses First Patient in Global Phase II Registrational Trial of Cadonilimab Plus Lenvatinib for IO-Pretreated Advanced HCC
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II regi...
September 16, 2025 | News
Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154
Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...
September 12, 2025 | News
Samsung Biologics Expands Presence in Japan with New Tokyo Office
Samsung Biologics has announced the opening of a new office in Tokyo, underscoring its long-term commitment to supporting Japan’s pharmaceutical and ...
September 09, 2025 | News
Huadong Medicine Reports Promising Phase I Results for Novel ROR1-Targeting ADC HDM2005 in Lymphoma
Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...
September 08, 2025 | News
China’s Biocytogen and Germany’s Merck KGaA Join Forces on Antibody-LNP Delivery Innovation
-Biocytogen Pharmaceuticals , a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative te...
September 05, 2025 | News
Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability
Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...
September 01, 2025 | Company results
Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager
Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...
August 26, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
